Amyloidosis trials in United Kingdom

In United Kingdom 20 Also abroad 184

20 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Where
Birmingham, Cardiff, Glasgow, Hexham, Liverpool, London, Manchester
Age
18 years to 90 years
People
1,200 worldwide
Run by
Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00
No phaseTaking people
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis
Where
Glasgow
Age
18 years and over
People
2,200 worldwide
Run by
Idoven 1903 S.L.
See details and how to joinNCT06978660
Phase 1Taking people
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Where
London, Sutton
Age
18 years and over
People
180 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Where
Liverpool, London
Age
18 years to 64 years
People
60 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07224672 · EU 2025-522803-60-00
Phase 3Enrolling by invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Bellshill, Birmingham, Cardiff, Hexham, London, Manchester
Age
18 years and over
People
700 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT06679946
Phase 3Taking people
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Where
Bellshill, Birmingham, Cardiff, Liverpool, London, Manchester
Age
18 years and over
People
1,280 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07207811
Phase 3Taking people
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Bellshill, Birmingham, Cardiff, London, Manchester
Age
18 years to 85 years
People
1,750 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00
Phase 3Taking people
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Where
London
Age
18 years to 85 years
People
125 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00
No phaseTaking people
A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting
Where
Multiple Locations
Age
18 years and over
People
2,000 worldwide
Run by
Bayer
See details and how to joinNCT07235462
No phaseTaking people
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Where
Birmingham, Glasgow, London
Age
18 years to 130 years
People
1,850 worldwide
Run by
AstraZeneca
See details and how to joinNCT06465810
No phaseTaking people
Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations
Where
Birmingham
Age
18 years and over
People
320 worldwide
Run by
AstraZeneca
See details and how to joinNCT07654855
No phaseTaking people
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
Where
London
People
52,121 worldwide
Run by
AstraZeneca
See details and how to joinNCT06355934
Phase 3Not yet taking people in United Kingdom
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
Where
Birmingham, Cardiff, Glasgow, London, Manchester
People
1,180 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00
Phase 1/2Taking people
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Where
London, Manchester
Age
18 years and over
People
220 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06292780 · EU 2023-507809-34-00
Phase 3Taking people
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Where
London
Age
18 years to 75 years
People
587 worldwide
Run by
Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00
Phase 2/3Enrolling by invitation
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
Where
London
Age
18 years and over
People
72 worldwide
Run by
Intellia Therapeutics
See details and how to joinNCT05697861 · EU 2023-507385-11-00
Phase 1/2Taking people
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
Where
London
Age
18 years and over
People
91 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07081646
No phaseTaking people
PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY
Where
London
Age
18 years and over
People
320
Run by
Richmond Research Institute
See details and how to joinNCT05098665
Phase 3Enrolling by invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Where
Bellshill, Cardiff, Edgbaston, Hampstead, Liverpool, London, Manchester
Age
18 years and over
People
1,400 worldwide
Run by
Ionis Pharmaceuticals, Inc.
See details and how to joinNCT05667493
No phaseTaking people
National Registry of Rare Kidney Diseases
Where
Bristol
People
35,000
Run by
UK Kidney Association
See details and how to joinNCT06065852